Kevin Cline, MD
Urology · Shreveport, LANPI 1699770107
Payments from drug & device makers
Across 656 payments — averaging $2043.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$363K
- Ortho-clinical Diagnostics, Inc.$344K
- AbbVie$242K
- Sumitomo Pharma America, Inc.$156K
- Bluewind Medical$73K
- Cytyc Surgical Products, LLC$56K
- plus $108K from 28 others
Across 19 payments — averaging $88.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 48 | $362,745 |
| Ortho-clinical Diagnostics, Inc. | 39 | $343,547 |
| AbbVie(2 entities) | 99 | $241,970 |
| Sumitomo Pharma America, Inc. | 22 | $155,605 |
| Bluewind Medical | 21 | $72,736 |
| Cytyc Surgical Products, LLC | 10 | $56,102 |
| Myriad Genetic Laboratories, Inc. | 1 | $43,200 |
| Ironwood Pharmaceuticals, Inc | 15 | $31,458 |
| GSK | 11 | $20,122 |
| Butterfly Network, Inc. | 1 | $4,838 |
| Medtronic(2 entities) | 273 | $2,945 |
| AstraZeneca | 1 | $1,800 |
| Valencia Technologies Corporation | 3 | $1,437 |
| Axonics, Inc. | 7 | $368 |
| Boston Scientific | 12 | $340 |
| Astellas Pharma US Inc | 18 | $247 |
| Johnson & Johnson | 23 | $243 |
| Endo Pharmaceuticals Inc. | 12 | $218 |
| Coloplast | 6 | $136 |
| Ferring Pharmaceuticals Inc. | 4 | $99 |
| Pfizer | 4 | $63 |
| Endo USA, Inc. | 3 | $54 |
| Calyxo, Inc. | 2 | $48 |
| Tolmar, Inc. | 3 | $48 |
| Merck | 2 | $43 |
| Neotract Inc. | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 2 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Cytyc Corporation | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $14 |
| SN Holdings, LLC | 5 | $0 |
| Urogpo LLC | 2 | $0 |
How this compares
$1,340,564 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Shreveport
- Ralph HendersonShreveport$4M
- Ashley BakerShreveport$705K
- Jared MossShreveport$365K
- James NobleShreveport$273K
- Jeremy NorwoodShreveport$128K
- Kevin HebertShreveport$54K
- Thomas PalmerShreveport$45K
- Nazih KhaterShreveport$23K
- David PriceShreveport$23K
- Tajammul FaziliShreveport$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.